Navigation Links
Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
Date:5/7/2008

shares of its series B convertible preferred stock. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contacts: Jack Lief Mary Claire Duch

President and CEO WeissComm Partners

Media Relations

David Walsey 212.301.7228

Director, Corporate Communications

Arena Pharmaceuticals, Inc.

858.453.7200, ext. 1682


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
10. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
11. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... -- According to a new market research report ... Cord Stimulation, Transcranial Magnetic Stimulation), Application (Depression, Parkinson,s, Tinnitus, Alzheimer,s, ... by MarketsandMarkets, the global Neuromodulation Market is estimated at $3.65 ... by 2020, at a CAGR of 11.2% during the forecast ... market data T ables and ...
(Date:7/2/2015)... Numotion,s Board of Directors and Mike ... Feitel has joined the Company as Chief Financial ... successful 18 year career at GE serving in executive ... productivity to result in significant industry leading growth and ... Officer for GE Healthcare Global Services, a $5B P&L ...
(Date:7/2/2015)... 25, 2015 ... the addition of the "2015 New ... Challenges, Emerging Technologies, Competitive Landscape" report ... Frontiers in Clinical Chemistry and Immunodiagnostics: Global ... new seven-country strategic analysis of major business ...
Breaking Medicine Technology:Neuromodulation Market Worth $6.20 Billion by 2020 2Neuromodulation Market Worth $6.20 Billion by 2020 3Neuromodulation Market Worth $6.20 Billion by 2020 4Numotion Names Tamas Feitel Chief Financial Officer 2New Frontiers in 2015 Global Clinical Chemistry and Immunodiagnostics Market: Challenges, Emerging Technologies, Competitive Landscape 2
... ... ... ... ...
... , ... ... ... ...
Cached Medicine Technology:STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 2STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 3STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 4STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 5STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 6STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 7STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 8STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 9STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 10STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 11STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 12STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 13STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 14STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 15STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 16STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 17Orexigen(R) Therapeutics Schedules March 9, 2010 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2009 2Orexigen(R) Therapeutics Schedules March 9, 2010 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2009 3
(Date:7/4/2015)... ... 2015 , ... Tyler Boden, Project Developer of Sullivan Solar ... the North American Board of Certified Energy Practitioners (NABCEP®), and is now a ... well established national certification organization for renewable energy professionals. Designation as a NABCEP ...
(Date:7/3/2015)... , ... July 03, 2015 , ... ... enrollment on July 2nd creating a buzz of media attention. In an effort ... online by HonestyFirstReviews.com's Tiffany Hendricks. , "These days many people are feeling overwhelmed ...
(Date:7/3/2015)... ... July 03, 2015 , ... Rheumatology ... 2015 Annual Conference , the premiere continuing education and networking event for ... SeaWorld in Orlando, Florida. Speakers include the leading rheumatology experts in immunology, ...
(Date:7/3/2015)... ... 03, 2015 , ... Renowned rhinoplasty surgeon and Symposium Chairman, ... Rhinoplasty Symposium . To be held from March 4th - 6th, the 2016 (a ... Westin Galleria Dallas. , Designed to take participants from the basic training and fundamentals ...
(Date:7/3/2015)... ... 03, 2015 , ... B. E. Smith, the only full-service ... a national chief nursing officer recruitment for Jane Phillips Medical Center ... industry, B. E. Smith has recently placed more than 1,000 healthcare executives into ...
Breaking Medicine News(10 mins):Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 3Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 2Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 3Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 2Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 3Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3
... finds , MONDAY, Dec. 7 (HealthDay News) A new ... in preventing dangerous venous clots as an old standby, warfarin, ... new study finds. , Dabigatran is marketed as Pradax in ... for use in the United States. , The new study, ...
... ... top-of-the-line implementation services to Talyst’s clients in the acute care industry. , ... (PRWEB) December ... the American Society of Health-System Pharmacists in Las Vegas, Talyst announced a partnership ...
... Dec. 7 Hoping to protect their children and grandchildren ... are prepared to make the difficult choices necessary to put ... clear in a report released today by The Concord Coalition ... by a grant from the Peter G. Peterson Foundation, the ...
... , ... 7 Stand Up To Cancer (SU2C) announced today that ... conducted by 13 young scientists. Over a three-year period, each ... part of SU2C,s Innovative Research Grants program, which supports the ...
... , NEW ORLEANS, Dec. 7 Micromet, ... novel, proprietary antibodies for the treatment of cancer, inflammation ... poster(1) with new data from its ongoing phase 1 ... with non-Hodgkin,s lymphoma (NHL) at the 51ST Annual Meeting ...
... , WALTHAM, Mass., Dec. 7 Interleukin Genetics, Inc. ... approval by the State of New York,s Department of Health ... Genetic Test that determines predisposition to severe periodontal disease in ... States in the U.S. However, through its Clinical Laboratory ...
Cached Medicine News:Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 2Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 3Health News:Talyst and RXinnovate Partner on Pharmacy Automation Implementation 2Health News:Concord Coalition Report Shows Eagerness for Reform, Readiness to Make Tough Choices on Fiscal Priorities 2Health News:Concord Coalition Report Shows Eagerness for Reform, Readiness to Make Tough Choices on Fiscal Priorities 3Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 2Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 3Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 4Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 5Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 6Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 7Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 8Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 9Health News:Data from Phase 1 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Non-Hodgkins Lymphoma 2Health News:Data from Phase 1 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Non-Hodgkins Lymphoma 3Health News:Data from Phase 1 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Non-Hodgkins Lymphoma 4Health News:Interleukin Genetics Receives Approval To Sell its PST(R) Periodontal Disease Genetic Test in New York 2Health News:Interleukin Genetics Receives Approval To Sell its PST(R) Periodontal Disease Genetic Test in New York 3
... 200 to 350 Liters of pure water, ... Distribution of Purified Water,Millipores compact S.D.S. Storage ... 200 to 350 liters of purified water ... to maintain consistent purity of stored water, ...
... 200 to 350 Liters of pure water, ... Distribution of Purified Water,Millipores compact S.D.S. Storage ... 200 to 350 liters of purified water ... to maintain consistent purity of stored water, ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
Medicine Products: